IP Library › Granted Patent US 9,981,020
Granted Patent B2
US 9,981,020 · App. 15/148,261 · Granted May 29, 2018

Methods and compositions for RNA-guided treatment of HIV infection

Inventors: Kamel Khalili (Bala Cynwyd, PA); Wenhui Hu (Cherry Hill, NJ)
Assignee: Temple University of the Commonwealth System of Higher Education
A61K38/465A61K9/0034A61K35/12A61K45/06A61K48/00A61K48/005C12N7/00C12N9/22C12N15/111C12N2310/20C12N2320/30C12N2740/16063C12Y301/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,981,020
App. No.
15/148,261
Granted
May 29, 2018
Kind
B2
Abstract

A method of inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus by treating the host cell with a composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) in the proviral DNA, and inactivating the proviral DNA. A composition for use in inactivating a proviral DNA integrated into the genome of a host cell latently infected with a retrovirus including isolated nucleic acid sequences comprising a CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a human immunodeficiency virus.

Claims (5)

1. A composition for inactivating an HIV-1 proviral DNA integrated into the genome of a host cell latently infected with a retrovirus comprising:

a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and two or more different multiplex guide RNAs (gRNAs), wherein each of the at least two gRNAs is complementary to a different target nucleic acid sequence in a long terminal repeat (LTR) of the HIV-1 proviral DNA, whereby treating the host cell with the composition cleaves a double strand of the HIV-1 proviral DNA at a first target protospacer sequence with the CRISPR-associated endonuclease and cleaves a double strand of the HIV-1 proviral DNA at a second target protospacer sequence with the CRISPR-associated endonuclease and thereby excises an entire HIV-1 proviral genome and eradicates the HIV-1 proviral DNA from the host cell.

2. The composition according to claim 1 , wherein said first target protospacer sequence and said second target protospacer sequence each include a sequence complementary to a target protospacer sequence selected from the group consisting of SEQ ID NO: 96, SEQ ID NO: 121, SEQ ID NO: 87, and SEQ ID NO: 110.

3. The composition according to claim 1 , wherein said first target protospacer sequence and said second target protospacer sequence include, respectively, a sequence complementary to target protospacer sequences SEQ ID NO: 96 and SEQ ID NO: 121.

4. The composition according to claim 1 , wherein said first target protospacer sequence and said second target protospacer sequence each include, respectively, a sequence complementary to target protospacer sequences SEQ ID NO: 87 and SEQ ID NO: 110.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2016
From: KHALILI, KAMEL; HU, WENHUI
To: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Reel/Frame 038486/0290 →
Continuity (5)
Continuation 14838057
Provisional Application 61871626 · Aug 29, 2013
Provisional Application 62018441 · Jun 27, 2014
Provisional Application 62026103 · Jul 18, 2014
Related Publication 20160250300A1 · Sep 1, 2016